参考文献

1.Cheng S，Vijayan A.The Washington manual nephrology subspecialty consult.3rd ed.Fer KEHTMD，editor.China:Department of Medicine，Washington University School of Medicine，2012.

2.American Diabetes Association.Microvascular complications and foot care.Diabetes Care，2015，38（Supplement 1）:S58-S66.

3.de Boer IH，Rue TC，Hall YN，et al.Temporal trends in the prevalence of diabetic kidney disease in the United States.JAMA，2011，305（24）:2532-2539.

4.Loh PT，Toh M，Molina JA，Vathsala A.Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster.Nephrology，2015，20（3）:216-223.

5.White S，Chadban S.KinD Reports（Kidneys in Diabetes）:temporal trends in the epidemiology of diabetic kidney disease and the associated health care burden in Australia.Kidney Health Australia，2014.

6.International Diabetes Federation.IDF Diabetes Atlas.7th ed.Brussels，Belgium，2015.

7.Kainz A，Hronsky M，Stel VS，et al.Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025.Nephrology Dialysis Transplantation，2015，30:113-118.

8.Young BA，Katon WJ，Von Korff N，et al.Racial and ethnic differences in microalbuminuria prevalence in a diabetes population:The pathways study.Clin J Am Soc Nephrol，2005，16（1）:219-228.

9.Jia WP，Gao X，Pang C，et al.Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation:Shanghai diabetic complications study（SHDCS）.Nephrology Dialysis Transplantation，2009，24（12）:3724-3731.

10.Yang CW，Park JT，Kim YS，et al.Prevalence of diabetic nephropathy in primary care type 2 diabetic patientswith　　hypertension:data　　from　　the　　Korean　　Epidemiology　　Study　　on Hypertension III（KEY III study）.Nephrology Dialysis Transplantation，2011，26（10）:3249-3255.

11.Hall V，Thomsen RW，Henriksen O，et al.Diabetes in Sub Saharan Africa 1999-2011:epidemiology and public health implications.a systematic review.BMC Public Health，2011，11:564.

12.da Silva PM，Carvalho D，Nazare J，et al.Prevalence of microalbuminuria in hypertensive patients with or without type 2 diabetes in a Portuguese primary care setting:The RACE（micRoAlbumin sCreening survEy） study.Revista Portuguesa De Cardiologia，2015，34（4）:237-246.

13.National Institutes of Health，National Institute of Diabetes and Digestive and Kidney Diseases.United States Renal Data System annual data report:Epidemiology of kidney disease in the United States，2014.

14.McDonald S.The 28th annual report:ANZDATA Australia and New Zealand dialysis and transplant registry.Australia and New Zealand dialysis and transplant registry，2006.

15.Afkarian M，Sachs MC，Kestenbaum B，et al.Kidney disease and increased mortality risk in type 2 diabetes.Clin J Am Soc Nephrol，2013，24（2）:302-308.

16.Global Burden of Disease 2013 Mortality and Causes of Death Collaborators.Global，regional，and national age-sex specific all-cause and cause-specific mortality for 240 causes of death，1990-2013:a systematic analysis for the Global Burden of Disease Study 2013.Lancet，2015，10；385（9963）:117-171.

17.White S，Chadban S.Diabetic kidney disease in Australia:current burden and future projections.Nephrology，2014，19（8）:450-458.

18.MacIsaac RJ，Ekinci EI，Jerums G.Markers of and risk factors for the development and progression of diabetic kidney disease.Am J Kidney Dis，2014，63（2）:S39-S62.

19.Mehler PS，Jeffers BW，Biggerstaff SL，et al.Smoking as a risk factor for nephropathy in noninsulin-dependent diabetics.J Gen Intern Med，1998，13（12）:842-845.

20.Saiki A，Nagayama D，Ohhira M，et al.Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy.Int J Obes，2005，29（9）:1115-1120.

21.Aggarwal J，Kumar M.Prevalence of microalbuminuria among rural north Indian population with diabetes mellitus and its correlation with glycosylated haemoglobin and smoking.J Clin Diagn Res，2014，8（7）:CC11-3.

22.Mann JFE，Gerstein HC，Yi Q-L，et al.Development of renal disease in people at high cardiovascular risk:results of the HOPE randomized study.J Am Soc Nephrol，2003，14（3）:641-647.

23.Tapp RJ SJ，Zimmet PZ，Balkau B，et al.Albuminuria is evident in the early stages of diabetes onset:results from the Australian Diabetes，Obesity，and Lifestyle Study（AusDiab）.Am J Kid Dis，2004，44（5）:792-798.

24.Cui WP，Du B，Cui YC，et al.Is rs759853 polymorphism in promoter of aldose reductase gene a risk factor for diabetic nephropathy?A meta-analysis.Eur J Med Res，2015，20（1）:14.

25.El-Baz R，Settin A，Ismaeel A，et al.MTHFR C677T，A1298C and ACE I/D polymorphisms as risk factors for diabetic nephropathy among type 2 diabetic patients.J Renin Angiotensin Aldosterone Syst，2012，13（4）:472-477.

26.Brancati FL WJ，Whelton PK，Seidler AJ，et al.The excess incidence of diabetic end-stage renal disease among blacks，a population-based study of potential explanatory factors.JAMA，1992，268（1）:3078-3084.

27.Nelson RG，Knowler WC，Pettitt DJ，et al.Diabetic kidney disease in Pima Indians.Diabetes Care，1993，16（1）:335-341.

28.Smith SR SL，Dennis VW.Racial differences in the incidence and progression of renal diseases.Kidney Int，1991，40（5）:815-822.

29.Cao Z，Cooper ME.Pathogenesis of diabetic nephropathy.J Diab Invest，2011，2（4）:243-247.

30.Brownlee M.Biochemistry and molecular cell biology of diabetic complications.Nature，2001，414（6865）:813-820.

31.Arora MK，Singh UK.Oxidative stress:meeting multiple targets in pathogenesis of diabetic nephropathy.Current Drug Targets，2014，15（5）:531-538.

32.Wada J，Makino H.Inflammation and the pathogenesis of diabetic nephropathy.Clin Sci，2013，124（3）:139-152.

33.Ruggenenti P，Cravedi P，Remuzzi G.The RAAS in the pathogenesis and treatment of diabetic nephropathy.Nat Rev Nephrol，2010，6（6）:319-330.

34.Adler S.Diabetic nephropathy:linking histology，cell biology，and genetics.Kidney Int，2004，66（5）:2095-2106.

35.Fioretto P，Steffes MW，Brown DM，Mauer SM.An overview of renal pathology in insulindependent diabetes mellitus in relationship to altered glomerular hemodynamics.Am J Kid Dis，1992，20（6）:549-558.

36.Kimmelstiel P，Wilson C.Intercapillary lesions in the glomeruli of the kidney.Am J Pathology，1936，12（1）:83-U30.

37.Tervaert TW，Mooyaart AL，Amann K，et al.Pathologic classification of diabetic nephropathy.J Am Soc Nephrol，2010，21（4）:556-563.

38.Rogers K.Diabetic Nephropathy.Britannica Academic:Encyclopedia Britannica Inc，2015.

39.Levin A，Rocco M.KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease.Am J Kid Dis，2007，49（2）:S10-S179.

40.Afkarian M，Zelnick LR，Hall YN，et al.Clinical manifestations of kidney disease among US adults with diabetes，1988-2014.JAMA，2016，316（6）:602-610.

41.MacIsaac RJ，Tsalamandris C，Panagiotopoulos S，et al.Nonalbuminuric renal insufficiency in Type 2 diabetes.Diabetes Care，2004，27:195-200.

42.Robles NR，Villa J，Gallego RH.Non-proteinuric diabetic nephropathy.J Clin Med，2015，4（9）:1761-1773.

43.中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识（2014年版）.中华糖尿病杂志，2014，6（11）:792-801.

44.DynaMed Plus.Diabetic nephropathy ［updated 2015 Feb 23；cited 2015 Oct 29］.［Available from:http://www.dynamed.com/topics/dmp～AN～T113702/Diabetic-nephropathy］.

45.Lewis G，Maxwell AP.Risk factor control is key in diabetic nephropathy.Practitioner，2014，258（1768）:13-17.

46.UK Prospective Diabetes Study（UKPDS）Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes（UKPDS 33）.Lancet，1998，352（9131）:837-853.

47.de Boer IH，Sun W，Cleary PA，et al.Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.NEJM，2011，365（25）:2366-2376.

48.Shamoon H，Duffy H，Fleischer N，et al.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes-mellitus.NEJM，1993，329（14）:977-986.

49.Tonna S，El-Osta A，Cooper ME，et al.Metabolic memory and diabetic nephropathy:potential role for epigenetic mechanisms.Nat Rev Nephrol，2010，6（6）:332-341.

50.National Kidney Foundation.KDOQI clinical practice guideline for diabetes and CKD:2012 Update.Am J Kid Dis，2012，60（5）:850-886.

51.Group AC，Patel A，MacMahon S，et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.NEJM，2008，358（24）:2560-2572.

52.Duckworth W，Abraira C，Moritz T，et al.Glucose control and vascular complications in veterans with type 2 diabetes.NEJM，2009，360（2）:129-139.

53.Molitch ME，Adler AI，Flyvbjerg A，et al.Diabetic kidney disease:a clinical update from kidney disease:improving global outcomes.Kidney Int，2015，87（1）:20-30.

54.Zanchi A，Lehmann R，Philippe J.Antidiabetic drugs and kidney disease—recommendations of the Swiss society for endocrinology and diabetology.Swiss Medical Weekly，2012，142:w13629.

55.中国医师协会内分泌代谢科医师分会.2型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识.中华内分泌代谢杂志，2016，32（6）:455-460.

56.Colhoun HM，Lee ET，Bennett PH，et al.Risk factors for renal failure:The WHO multinational study of vascular disease in diabetes.Diabetologia，2001，44:S46-S53.

57.Ravid M，Brosh D，Ravid-Safran S，et al.Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels，mean blood pressure，and hyperglycemia.Arch Intern Med，1998，158（9）:998-1004.

58.Atkins RC，Briganti EM，Lewis JB，et al.Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.Am J Kid Dis，2005，45（2）:281-287.

59.Brenner BM，Cooper ME，de Zeeuw D，et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.NEJM，2001，345（12）:861-869.

60.Lewis EJ，Hunsicker LG，Bain RP，et al.The effect of angiotensin-converting enzymeinhibition on diabetic nephropathy.NEJM，1993，329（20）:1456-1462.

61.Lewis EJ，Hunsicker LG，Clarke WR，et al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.NEJM，2001，345（12）:851-860.

62.Lv J，Perkovic V，Foote CV，et al.Antihypertensive agents for preventing diabetic kidney disease.Cochrane Database Syst Rev，2012，12:CD004136.

63.Strippoli GF，Bonifati C，Craig M，et al.Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.Cochrane Database Syst Rev，2006，4:CD006257.

64.Haller H，Ito S，Izzo JL，et al.Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.NEJM，2011，364（10）:907-917.

65.Palmer SC，Mavridis D，Navarese E，et al.Comparative efficacy and safety of blood pressurelowering agents in adults with diabetes and kidney disease:a network meta-analysis.Lancet，2015，385（9982）:2047-2056.

66.Fried LF，Emanuele N，Zhang JH，et al.Combined angiotensin inhibition for the treatment of diabetic nephropathy.NEJM，2013，369（20）:1892-1903.

67.Quiroga B，Fernandez Juarez G，Luno J.Combined angiotensin inhibition in diabetic nephropathy.NEJM，2014，20；370（8）:777.

68.Best M，de Wever J，Smulders Y.Combined angiotensin inhibition in diabetic nephropathy.NEJM，2014，370（8）:778.

69.Izumi Y，Kawahara K，Nonoguchi H.Combined angiotensin inhibition in diabetic nephropathy.NEJM，2014，370（8）:777-778.

70.Nikolaidou B，Lazaridis A，Doumas M.Combined angiotensin inhibition in diabetic nephropathy.NEJM，2014，370（8）:778-779.

71.Kidney disease:Improving global outcomes（KDIGO）blood pressure work group.KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease.Kidney International Supplements，2012，2（5）:337-414.

72.Bakris GL，Copley JB，Vicknair N，et al.Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.Kidney Int，1996，50（5）:1641-1650.

73.Bakris GL，Toto RD，McCullough PA，et al.Effects of different ACE inhibitor combinations on albuminuria:results of the GUARD study.Kidney Int，2008，73（11）:1303-1309.

74.Liu LC SE，Gansevoort RT，van der Meer P，et al.Third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.Expert Opin Investig Drugs，2015，24（8）:1123-1135.

75.Bakris GL，Agarwal R，Chan JC，et al.Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial.JAMA，2015，314（9）:884-894.

76.Jenkins AJ，Lyons TJ，Zheng D，et al.Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort:associations with gender and glycemia.Diabetes Care，2003，26（3）:810-808.

77.Morton J，Zoungas S，Li Q，et al.Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy:results of the ADVANCE study.Diabetes Care，2012，35（11）:2201-2206.

78.Tolonen N，Forsblom C，Thorn L，et al.Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.Diabetologia，2009，52（12）:2522-2530.

79.Baigent C，Landray MJ，Reith C，et al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease（Study of Heart and Renal Protection）:a randomised placebo-controlled trial.Lancet，2011，377（9784）:2181-2192.

80.Palmer SC，Navaneethan SD，Craig JC，et al.HMG CoA reductase inhibitors（statins）for people with chronic kidney disease not requiring dialysis.Cochrane Database Syst Rev，2014，5:CD007784.

81.Gaede P，Lund-Andersen H，Parving HH，et al.Effect of a multifactorial intervention on mortality in type 2 diabetes.NEJM，2008，358（6）:580-591.

82.Ismail-Beigi F，Craven TE，O′Connor PJ，et al.Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.Kidney Int，2012，81（6）:586-594.

83.Dwyer JP，Greco BA，Umanath K，et al.Pyridoxamine dihydrochloride in diabetic nephropathy（PIONEER-CSG-17）:lessons learned from a pilot study.Nephron，2015，129（1）:22-28.

84.Hovind P，Rossing P，Johnson R，et al.Serum uric acid as a new player in the development of diabetic nephropathy.J Renal Nutrition，2011，21（1）:124-127.

85.McCormick BB，Sydor A，Akbari A，et al.The effect of pentoxifylline on proteinuria in diabetic kidney disease:a meta-analysis.Am J Kidney Dis，2008，52（3）:454-463.

86.Foley RN，Murray AM，Li S，et al.Chronic kidney disease and the risk for cardiovascular disease，renal replacement，and death in the United States Medicare population，1998 to 1999.J Am Soc Nephrol，2005，16（2）:489-495.

87.Bragg F，Holmes MV，Iona A，et al.Association between diabetes and cause-specific mortality in rural and urban areas of China.JAMA，2017，317（3）:280-289.

88.Taal MW CG，Marsden PA，Skorecki K，et al.Brenner and Rector′s The Kidney E-Book:Elsevier Health Sciences，2011.

89.Longenecker JC，Coresh J，Powe NR，et al.Traditional cardiovascular disease risk factors in dialysis patients compared with the general population:the CHOICE Study.JASN，2002，13（7）:1918-1927.

90.Groop PH，Thomas MC，Moran JL，et al.The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes.Diabetes，2009，58（7）:1651-1658.